MAPT Protocol: Fixation Versus Arthroplasty Surgical Treatments for Early Recovery After HIP Fracture (FASTER-HIP)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorUniversity of Southern California

About this trial

This study is an intervention domain of the Musculoskeletal Adaptive Platform Trial. The primary goal of this pragmatic, randomized, open-label, comparative effectiveness trial is to evaluate if arthroplasty is superior to internal fixation when used to treat minimally displaced femoral neck fractures in older adults ≥60 years old. We hypothesize that arthroplasty will reduce death, preserve ambulation, increase days alive and out of hospital, and improve health status compared to internal fixation within 4 months and 12 months from randomization.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

60 years of age or older undergoing surgery due to a minimally displaced femoral neck fracture

The patient has a health condition affecting physical mobility.

Complete fracture of the femoral neck (AO/OTA 31B) confirmed with anteroposterior and lateral hip radiographs, computed tomography, or magnetic resonance imaging.

Minimally displaced fracture that could be, in the judgment of the attending surgeon, managed with either arthroplasty or in situ internal fixation without reduction.

Disqualifiers

The patient is not clinically suitable for either compared treatment.

Expected injury survival of less than 12 months.

Terminal illness with expected survival of less than 12 months.

Incarceration.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Hip arthroplasty

    Procedure/Surgery

    Participants will undergo surgical treatment using standard hip arthroplasty techniques for femoral minimally displaced femoral neck fracture. A modern porous-coated press-fit or cemented hip arthroplasty prosthesis will be used at the treating surgeon's discretion. Press-fit implants that have no ingrowth or ongrowth surface will not be permitted. The type of hip prosthesis (hemiarthroplasty or total hip arthroplasty), bearing (single or dual mobility), or the method of arthroplasty fixation (cemented or uncemented) will be at the discretion of the treating surgeon.

  • Internal fixation

    Procedure/Surgery

    Participants will undergo surgical treatment using standard fixation techniques for minimally displaced femoral neck fractures. The treating surgeon may perform fracture reduction maneuvers if desired. Fixed-angle devices and multiple screws will be permitted. The internal fixation device(s) will be inserted through a small lateral incision. Internal fixation constructs combining cancellous screws and fixed-angle devices will be permitted.

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: Hip arthroplastyActive comparator 1 intervention
Group B: Internal fixationActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Composite outcome of death, ambulation status, and days alive and out of hospital.

Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below: * Days not alive. * Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.

Time frame
120 days after randomization

Secondary outcomes

1

Composite outcome of death, ambulation status, and days alive and out of hospital.

Death consists of time to all-cause mortality. Ambulation will be evaluated using an ordinal ranking of independence. Days alive and out of hospital will be calculated by subtracting the sum of days meeting one of two criteria below: * Days not alive. * Any day on which the participant had an overnight stay in a hospital, inpatient rehabilitation, skilled nursing facility, nursing home, inpatient mental health care facility, or long-term care facility.

Time frame
365 days after randomization
2

Death

Death consists of time to all-cause mortality.

Time frame
120 days post-randomization
3

Death

Death consists of time to all-cause mortality.

Time frame
12 months post-randomization
4

Ambulation status

Ambulation will be evaluated using an ordinal ranking of independence

Time frame
120 days post-randomization

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Southern California

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator

McMaster University

Collaborator

University of Maryland, Baltimore

Collaborator

Evellere Group

Collaborator